Clinical trials: First-Episode Psychosis
Psychotic Disorders, Autism Spectrum Disorder
EEG Microstates Across At-Risk Mental States
The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6).
- Conditions
- Psychotic Disorders, Autism Spectrum Disorder, Major Depressive Disorder, Schizophrenia
- Trial name
- DEMETER (NCT06045897)
- Testing
- EEG 64 channels, Polysomnography 19 electrodes, Light hypnosis
- Where
- France
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia, Schizophreniform Disorder
Biomarkers in First Episode Schizophrenia
This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type
- Trial name
- NCT02033382
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Psychosis, First Episode Psychosis
Feasibility of an Early Detection Program for Early Psychosis on a College Campus
The objective of the proposed study is to determine the feasibility of an Early Detection program that aims to: (i) identify college students at clinical high risk (CHR) of psychosis or with first episode psychosis (FEP), and…
- Conditions
- Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
- Trial name
- NCT03983421
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2 (NCT02305823)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
First-Episode Psychosis, Bipolar Disorder
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders.
- Trial name
- CARB (NCT02334904)
- Testing
- Aripiprazole, Risperidone
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Psychosis
Narrative Identity and Its Relationship to Subjective Multidimensional Well-being in First Episode Psychosis
The transition between adolescence and adulthood (generally defined as ages 18 to 25) is a key developmental window for narrative identity and psychotic disorders. Narrative identity is positively associated with mental health.
- Trial name
- PEPsy-Identity (NCT06464848)
- Testing
- Narrative identity task
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
First Episode Psychosis
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs
Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC).
- Trial name
- NCT04005378
- Testing
- CSC Step-down intervention, Usual Care
- Where
- 3 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Schizophrenia
Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients
The aim of the study is to evaluate the effects of repetitive transcranial magnetic stimulation(rTMS)in the first-episode Schizophrenic patients: the clinical and MRI findings
- Trial name
- rTMSfMRI (NCT01370291)
- Testing
- active Risperidone and active rTMS
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Schizophrenia, Psychotic Disorders
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
This study compares the efficacy and effectiveness of two of the second-generation antipsychotics (SGAs) most used in our society in the treatment of schizophrenia (Aripiprazole and Risperidone) and the investigators do within an…
- Trial name
- PAFIP3_1Y (NCT02532491)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
First Episode Psychosis (FEP)
Self-administered COgnitive Personalized Training in Early Psychosis
The overall objective of SCOPe is to improve early intervention in psychosis by providing an innovative eHealth tool that will enable personalized cognitive training, adapted to the individual's cognitive abilities.
- Trial name
- SCOPe (NCT06634446)
- Testing
- a mobile application for cognitive training, video games
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Psychosis, Schizoaffective Disorder
OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis
The research team will develop and test a prototype version of OnTrack>An Online Role-Playing Game (OnTrack>The Game or OTG), an online role-playing game designed for youth and young adults experiencing First Episode Psychosis…
- Conditions
- Psychosis, Schizoaffective Disorder, Schizophrenia
- Trial name
- NCT03390491
- Testing
- OnTrack>TheGame (OTG), Recovery Videos (RV)
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Center for Social Innovation, Massachusetts
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Conditions
- Schizophrenia, Psychotic Disorders, Psychosis
- Trial name
- PAFIP3_nc3Y (NCT03883204)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
Standard Comprehensive Intervention to Treat First-episode Schizophrenia
Schizophrenia is not a curable but a treatable disease by antipsychotics. Kinds of atypical antipsychotics are widely used since 1990s' in China.
- Trial name
- NCT01057849
- Testing
- risperidone, olanzapine, Aripiprazole
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Peking University
Schizophrenia Disorder, Schizophreniform Disorder
MicroRNAs as Biomarkers in First Episode Schizophrenia
This study investigates whether tiny molecules called microRNAs (miRNAs), found in special brain-derived "packages" (neural-derived extracellular vesicles, or NDEs) that travel from the brain into the blood, can serve as helpful…
- Conditions
- Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
- Trial name
- MIRFEST (NCT07703670)
- Testing
- Plasma NDE miRNA Sequencing, Whole Genome Sequencing
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Early-onset Schizophrenia, Psychotic Disorders
Computerized Cognitive Remediation Therapy in Adolescents With a First Psychotic Episode
Cognitive deficits (CD) are considered one of the essential characteristics in psychotic disorders and occur throughout the course of the disease, being a key characteristic in the evolution of the disease and in the…
- Conditions
- Early-onset Schizophrenia, Psychotic Disorders, Cognitive Remediation Therapy, Cognition
- Trial name
- CCRT2019 (NCT05405946)
- Testing
- Computerized Cognitive Remediation Therapy, Treatment as Usual
- Where
- Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fundació Sant Joan de Déu
Psychoses
Brain Cell Injury in Patients With A First Episode of Psychosis
Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences…
- Trial name
- NCT00070889
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)